Aequus Pharmaceuticals Inc. (AQS.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.38 Million CAD | 75.16% |
| 2022 | 3.07 Million CAD | 20.03% |
| 2021 | 2.55 Million CAD | -0.07% |
| 2020 | 2.56 Million CAD | 0.43% |
| 2019 | 2.54 Million CAD | 709.71% |
| 2018 | 314.89 Thousand CAD | -14.16% |
| 2017 | 366.83 Thousand CAD | -50.72% |
| 2016 | 744.41 Thousand CAD | -34.99% |
| 2015 | 1.14 Million CAD | 53.8% |
| 2014 | 744.5 Thousand CAD | 1212.23% |
| 2013 | 56.73 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 6.62 Million CAD | 9.65% |
| 2024 Q1 | 6.04 Million CAD | 12.27% |
| 2023 Q3 | 4.75 Million CAD | 29.34% |
| 2023 FY | 5.38 Million CAD | 75.16% |
| 2023 Q4 | 5.38 Million CAD | 13.06% |
| 2023 Q1 | 3.08 Million CAD | 0.36% |
| 2023 Q2 | 3.67 Million CAD | 19.36% |
| 2022 Q1 | 2.65 Million CAD | 3.71% |
| 2022 Q3 | 3.03 Million CAD | 23.85% |
| 2022 Q2 | 2.45 Million CAD | -7.62% |
| 2022 FY | 3.07 Million CAD | 20.03% |
| 2022 Q4 | 3.07 Million CAD | 1.15% |
| 2021 Q1 | 2.45 Million CAD | -4.29% |
| 2021 FY | 2.55 Million CAD | -0.07% |
| 2021 Q4 | 2.55 Million CAD | 1.57% |
| 2021 Q3 | 2.51 Million CAD | 4.61% |
| 2021 Q2 | 2.4 Million CAD | -1.73% |
| 2020 Q2 | 2.75 Million CAD | 1.25% |
| 2020 Q3 | 3.06 Million CAD | 11.57% |
| 2020 Q4 | 2.56 Million CAD | -16.57% |
| 2020 FY | 2.56 Million CAD | 0.43% |
| 2020 Q1 | 2.71 Million CAD | 6.56% |
| 2019 Q3 | 2.43 Million CAD | 4.69% |
| 2019 Q1 | 935.34 Thousand CAD | 197.03% |
| 2019 Q2 | 2.32 Million CAD | 148.88% |
| 2019 Q4 | 2.54 Million CAD | 4.62% |
| 2019 FY | 2.54 Million CAD | 709.71% |
| 2018 Q4 | 314.89 Thousand CAD | -41.67% |
| 2018 Q2 | 569.63 Thousand CAD | 43.52% |
| 2018 Q1 | 396.89 Thousand CAD | 8.19% |
| 2018 FY | 314.89 Thousand CAD | -14.16% |
| 2018 Q3 | 539.83 Thousand CAD | -5.23% |
| 2017 Q4 | 366.83 Thousand CAD | -34.0% |
| 2017 Q1 | 657.14 Thousand CAD | -11.72% |
| 2017 FY | 366.83 Thousand CAD | -50.72% |
| 2017 Q2 | 848.39 Thousand CAD | 29.1% |
| 2017 Q3 | 555.84 Thousand CAD | -34.48% |
| 2016 Q1 | 570.71 Thousand CAD | -50.16% |
| 2016 Q2 | 1.08 Million CAD | 89.88% |
| 2016 FY | 744.41 Thousand CAD | -34.99% |
| 2016 Q4 | 744.41 Thousand CAD | 5.42% |
| 2016 Q3 | 706.1 Thousand CAD | -34.84% |
| 2015 Q1 | 372.8 Thousand CAD | -49.93% |
| 2015 Q3 | 944.1 Thousand CAD | 101.77% |
| 2015 FY | 1.14 Million CAD | 53.8% |
| 2015 Q4 | 1.14 Million CAD | 21.29% |
| 2015 Q2 | 467.91 Thousand CAD | 25.51% |
| 2014 Q4 | 744.5 Thousand CAD | 130.88% |
| 2014 Q3 | 322.46 Thousand CAD | 0.0% |
| 2014 Q1 | - CAD | -100.0% |
| 2014 FY | 744.5 Thousand CAD | 1212.23% |
| 2013 FY | 56.73 Thousand CAD | 0.0% |
| 2013 Q4 | 56.73 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| CanadaBis Capital Inc. | 15.61 Million CAD | 65.554% |
| Decibel Cannabis Company Inc. | 96.79 Million CAD | 94.442% |
| Delivra Health Brands Inc. | 4.85 Million CAD | -10.747% |
| Entourage Health Corp. | 178.68 Million CAD | 96.989% |
| Lifeist Wellness Inc. | 9.94 Million CAD | 45.878% |
| Cannara Biotech Inc. | 61.77 Million CAD | 91.291% |
| Medicure Inc. | 8.16 Million CAD | 34.092% |
| PharmaCielo Ltd. | 23.96 Million CAD | 77.554% |
| Rubicon Organics Inc. | 16.99 Million CAD | 68.346% |
| BioSyent Inc. | 6.76 Million CAD | 20.521% |
| Voyageur Pharmaceuticals Ltd. | 727.87 Thousand CAD | -639.145% |